Tenoxicam

Tenoxicam, sold under the brand name Mobiflex among others, is a nonsteroidal anti-inflammatory drug (NSAID). It is used to relieve inflammation, swelling, stiffness, and pain associated with rheumatoid arthritis, osteoarthritis, ankylosing spondylitis (a type of arthritis involving the spine), tendinitis (inflammation of a tendon), bursitis (inflammation of a bursa, a fluid-filled sac located around joints and near the bones), and periarthritis of the shoulders or hips (inflammation of tissues surrounding these joints).[1]

Tenoxicam
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration		Oral
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
Pharmacokinetic data
Protein bindingHigh
Elimination half-life30–140 hours
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEBI
CompTox Dashboard (EPA)
ECHA InfoCard100.149.365
Chemical and physical data
FormulaC13H11N3O4S2
Molar mass337.37 g·mol−1
Melting point209 to 213 °C (408 to 415 °F) (dec.)
 NY (what is this?)  (verify)

Tenoxicam belongs to the class of NSAIDs known as oxicams.

It was patented in 1974 by Roche and approved for medical use in 1987.[2] It is available as a prescription-only drug in the United Kingdom and other countries, but not in the US. Outside the United Kingdom, tenoxicam is also marketed under brand names including Tilatil, Tilcitin, and Alganex.[1][3]

Contraindications

The drug is contraindicated for patients who are seniors who have been given anesthesia or surgery; are at risk of increased bleeding or kidney failure; have an active inflammatory disease involving the stomach or intestine (like ulcerative colitis); have an active stomach or intestinal ulcer; have had an acute asthmatic attack, hives, rhinitis (inflammation of the inner lining of the nasal passage), or other allergic reactions caused by Aspirin or other nonsteroidal anti-inflammatory drugs (for example diclofenac, ibuprofen, indomethacin, naproxen).[4][5]

Common side effects that have been observed with tenoxicam include peptic ulceration, dyspepsia, nausea, constipation, abdominal pain, diarrhea, rash, headache, edema, renal failure, and vertigo.[6][5][7] In rare cases, tenoxicam and other NSAIDs can contribute to thrombotic events, Stevens-Johnson Syndrome, and toxic epidermal necrolysis.[8][9][10]

Pregnancy and breastfeeding

It is not recommended that women who are trying to conceive, who are pregnant, or who are breastfeeding take tenoxicam. Tenoxicam can be taken in the first and second trimester when necessary, but it is a contraindication in the third trimester. Some studies have looked at whether or not NSAIDs are able to enter the breast milk and the first few studies have found evidence that NSAIDs can be found in breast milk. Therefore, it is not recommended that women take tenoxicam while breastfeeding.[6][5][7]

Interactions

Taking tenoxicam with other drugs can increase the chance of side effects or alter the therapeutic effect of tenoxicam or the other drug, depending on the combination. Drug types the tenoxicam may interact with include: other analgesic NSAIDs, salicylates such as aspirin, antacids, anticoagulants, cardiac glycosides, ciclosporin, quinolone antibiotics, lithium therapy, diuretics and anti-hypertensives, methotrexate, oral anti-diabetics, colestyramine, dextromethorphan, mifepristone, corticosteroids, anti-platelet agents and selective serotonin reuptake inhibitors (SSRIs), tacrolimus, zidovudine, and gold/penicillamine.[6][5][7]

Mechanism of action

Like all NSAIDs, the exact mechanism of action of tenoxicam is unknown. Involved in the mechanism of action is inhibition of cyclooxygenase (COX-1 and COX-2) which leads to the potential adverse effect of increased bleeding.[6]

Society and culture

Tenoxicam is sold in the form of 20 milligram tablets with the price of treatment ranging from US$1.29-2.73 per tablet.[11] Recommended dosing calls for tenoxicam to be taken once daily with food. One week is the typical length for treatment, but the treatment length may be extended.[6]

In 2008, the reported sales level for Tilcotil (tenoxicam) was 70 million SEK (approximately $10.5 million USD).[11][12]

Research

The first members of the oxicam family of NSAIDs were brought to market in France in 1982.[13] Shortly thereafter, tenoxicam went to phase III clinical trials for approval as use as an analgesic began in the 1980s. The general consensus from clinical studies is that tenoxicam has about equal analgesic effect as other NSAIDs and does not elicit any important side effects. More recent clinical trials for tenoxicam are examining the use of tenoxicam independently and in combination with other drugs for more specialized analgesic purposes in surgical operations such as third molar extraction and labor pains.[14][15][16]

gollark: It's not particularly evil, since it will only be used to identify opting-in things.
gollark: But I skimmed a paper on it and apparently the randomization can be workarounded in some cases by sending RTS frames with the device's "hardcoded" MAC address and seeing if you get a CTS frame back.
gollark: This would have been doable by just checking the MAC address against a list several years ago, but evil beeoids also did this so now phones and such have randomization.
gollark: Well, for convoluted reasons, I want to detect known devices within wireless range.
gollark: Request to send.

See also

References
  1. "Medicines A-Z - Tenoxicam". NHS. Retrieved July 3, 2015.
  2. Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 519. ISBN 9783527607495.
  3. "Drugs.com international listings for Tenoxicam". Drugs.com. Retrieved July 3, 2015.
  4. NHS Patient warnings Page accessed July 3, 2015
  5. "Mobiflex Tablets 20mg - Summary of Product Characteristics (SPC) - (eMC)". www.medicines.org.uk. Retrieved 2015-12-07.
  6. "Incepta Pharmaceuticals | Product details". www.inceptapharma.com. Retrieved 2015-12-07.
  7. Tilcotil. (2010). New Zealand Consumer Medicine Information. http://www.medsafe.govt.nz/consumers/cmi/t/tilcotil.pdf
  8. Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, et al. (January 2008). "Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study". The Journal of Investigative Dermatology. 128 (1): 35–44. doi:10.1038/sj.jid.5701033. PMID 17805350.
  9. Harr T, French LE (December 2010). "Toxic epidermal necrolysis and Stevens-Johnson syndrome". Orphanet Journal of Rare Diseases. 5 (1): 39. doi:10.1186/1750-1172-5-39. PMC 3018455. PMID 21162721.
  10. "Assessment report for Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and cardiovascular risk" (PDF). European Medicines Agency. 18 October 2012.
  11. "Tenoxicam 20 mg Price Comparisons - Online Pharmacies and Discount Coupons". www.pharmacychecker.com. Retrieved 2015-12-07.
  12. "Exchange Rate Average (Swedish Krona, US Dollar) - X-Rates". www.x-rates.com. Retrieved 2015-12-07.
  13. Penso D, Roujeau JC, Guillaume JC, Revuz J, Touraine R (February 1986). "Toxic epidermal necrolysis after oxicam use". Journal of the American Academy of Dermatology. 14 (2 Pt 1): 275–6. doi:10.1016/s0190-9622(86)80342-5. PMID 3485122.
  14. "Search of: tenoxicam - List Results - ClinicalTrials.gov". www.clinicaltrials.gov. Retrieved 2015-12-07.
  15. Ilhan O, Agacayak KS, Gulsun B, Koparal M, Gunes N (January 2014). "A comparison of the effects of methylprednisolone and tenoxicam on pain, edema, and trismus after impacted lower third molar extraction". Medical Science Monitor. 20: 147–52. doi:10.12659/MSM.890239. PMC 3915002. PMID 24473372.
  16. Mathias Filho AP, Sidi A (1985). "Long-term study with Ro 12-0068 (tenoxicam) in the treatment of rheumatoid arthritis". European Journal of Rheumatology and Inflammation. 8 (1): 3–8. PMID 3915886.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.